| GAL3ST1 — Cerebroside Sulfotransferase |
|---|
| Protein Name | Cerebroside Sulfotransferase (CST) |
| Gene | [GAL3ST1](/genes/gal3st1) |
| UniProt ID | [Q04589](https://www.uniprot.org/uniprot/Q04589) |
| Chromosomal Location | 22q13.33 |
| Molecular Weight | ~46 kDa (423 amino acids) |
| Subcellular Localization | Golgi apparatus |
| Protein Family | Sulfotransferase family |
| EC Number | 2.8.2.21 |
GAL3ST1 (Galactose-3-O-Sulfotransferase 1), also known as cerebroside sulfotransferase (CST), is a critical enzyme in the biosynthesis of sulfatides—sulfated galactocerebrosides that are essential components of the myelin sheath. This enzyme catalyzes the final step in sulfatide production, transferring a sulfate group from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to galactocerebroside, converting it to sulfatide (3-O-sulfo-galactosylceramide).
In the nervous system, GAL3ST1 is absolutely required for normal central and peripheral nervous system myelination. The enzyme is primarily expressed in oligodendrocytes (CNS) and Schwann cells (PNS), where it generates the sulfatides essential for myelin membrane stability and function. GAL3ST1 deficiency causes metachromatic leukodystrophy (MLD), a fatal autosomal recessive demyelinating disorder, while alterations in sulfatide metabolism have been implicated in multiple sclerosis, Alzheimer's disease, and other neurodegenerative conditions .
¶ Domain Architecture and Catalytic Mechanism
GAL3ST1 is a type II transmembrane protein with a characteristic domain organization:
- N-terminal cytosolic tail: Short (15-20 aa) cytosolic domain containing sorting signals
- Transmembrane helix: Single-pass transmembrane domain anchoring the protein in the Golgi membrane
- Stem region: Extended lumenal region connecting TM to catalytic domain
- C-terminal catalytic domain: ~380 aa sulfotransferase domain facing the Golgi lumen
The catalytic domain contains the conserved sulfotransferase fold and the PAPS-binding site. Structural studies have identified key residues involved in substrate recognition and catalysis .
GAL3ST1 exhibits the following enzymatic properties:
| Property |
Specification |
| Substrate |
Galactocerebroside (GalCer) + PAPS |
| Product |
Sulfatide (3-O-sulfo-GalCer) + PAP |
| pH optimum |
6.5-7.5 (Golgi lumen) |
| Km for GalCer |
~5 μM |
| Km for PAPS |
~2 μM |
| Localization |
Golgi apparatus (cisternal membranes) |
The reaction mechanism involves:
- PAPS binding to the catalytic site
- Galactocereside (from ceramide + UDP-galactose) binding
- Sulfate transfer to the C3 hydroxyl of galactose
- Release of sulfatide and PAP
GAL3ST1 activity is regulated at multiple levels:
- Transcriptional regulation: PPARγ agonists increase expression; oleic acid suppresses
- Substrate availability: Galactocerebroside levels determine reaction rate
- PAPS availability: Sulfate donor concentration limits catalysis
- Protein trafficking: Golgi localization is essential for function
- Developmental regulation: Expression increases during active myelination
GAL3ST1 catalyzes the final step in the sulfatide biosynthesis pathway:
flowchart TD
A["Ceramide"] --> B["Galactocerebroside<br/>GalCer"]
B --> C{"GAL3ST1"}
C -->|"PAPS"| D["Sulfatide"]
D --> E["Myelin membrane"]
D --> F["Plasma membrane"]
G["UGT8"] --> B
H["PAPS"] --> C
I["PAP"] --> J["Released"]
classDef blue fill:#e1f5fe,stroke:#0277bd
classDef green fill:#c8e6c9,stroke:#2e7d32
classDef orange fill:#fff3e0,stroke:#ef6c00
class A,G blue
class B,C,H green
class D,E,F orange
class I blue
¶ Myelin Formation and Maintenance
Sulfatides generated by GAL3ST1 are essential for myelin:
- Sulfatides comprise 5-15% of total myelin lipids (highest in PNS)
- Concentrated in the outer leaflet of myelin membranes
- Enriched at the intraperiod line (non-compact myelin)
- Present at high concentrations at nodes of Ranvier
- Membrane stability: Sulfate group provides negative charge, enabling electrostatic interactions
- Compaction: Sulfatides participate in myelin compaction
- Protein organization: Interact with myelin proteins (PLP, MBP)
- Water homeostasis: Sulfatide-regulated ion and water balance
Sulfatides mediate critical oligodendrocyte-axon communications:
- Axonal support: Sulfatides promote axonal viability through trophic support
- Node of Ranvier: Proper sulfatide distribution is essential for sodium channel clustering
- Metabolic coupling: Facilitate metabolite exchange between oligodendrocytes and axons
- Axonal transport: Sulfatide deficiency impairs axonal transport machinery
GAL3ST1 is expressed in immune cells and modulates immune responses:
- CD1d ligand: Sulfatides are ligands for CD1d on antigen-presenting cells
- NKT cell development: Sulfatide-CD1d interactions influence NKT cell populations
- Macrophage function: Affects phagocytosis and cytokine production
- Autoimmunity: Loss of sulfatides may contribute to autoimmune demyelination
GAL3ST1 exhibits region-specific expression correlating with white matter:
| Brain Region |
Expression Level |
Primary Cell Types |
| White matter |
Very high |
Oligodendrocytes |
| Corpus callosum |
High |
Oligodendrocytes |
| Cerebellum |
High |
Oligodendrocytes |
| Brainstem |
High |
Oligodendrocytes |
| Spinal cord |
High |
Oligodendrocytes |
| Gray matter |
Low |
Scattered oligodendrocytes |
- Expression pattern: Highest in mature oligodendrocytes
- Subcellular localization: Golgi apparatus, where sulfatide synthesis occurs
- Developmental regulation: Expression peaks during active myelination (postnatal weeks 2-4 in mouse)
- Lineage: Both pre-myelinating and myelinating oligodendrocytes express GAL3ST1
- Expression: High in myelinating Schwann cells
- Function: Generates PNS myelin sulfatides
- PNS-CNS differences: Higher sulfatide content in PNS myelin
- Astrocytes: Low expression; may contribute to sulfatide turnover
- Neurons: Minimal expression; acquire sulfatides from glial cells
- Microglia: Some expression; role in immune modulation
GAL3ST1 deficiency causes MLD, a paradigmatic demyelinating disorder:
- Enzymatic deficiency: Loss of cerebroside sulfotransferase activity
- Substrate accumulation: Galactocerebroside accumulates in oligodendrocytes/Schwann cells
- Product deficiency: Sulfatide deficiency in myelin membranes
- Dual toxicity: Both accumulation and deficiency cause pathology
- Infantile form: Most common; onset 1-2 years; rapid progression
- Juvenile form: Onset 4-12 years; slower progression
- Adult form: Onset after 12 years; variable; often misdiagnosed
- Diffuse demyelination throughout CNS and PNS
- Accumulation of galactocerebroside in macrophages
- Progressive white matter degeneration
- Axonal loss in later stages
GAL3ST1 and sulfatide metabolism are implicated in MS:
- Demyelination: Sulfatide loss is a hallmark of demyelinating lesions
- Remyelination failure: Failure of oligodendrocyte precursor differentiation may involve sulfatide synthesis defects
- Autoimmunity: Sulfatide-CD1d-NKT cell axis may be relevant to MS pathogenesis
- Therapeutic relevance: Enhancing sulfatide synthesis may promote remyelination
Emerging evidence links GAL3ST1 to AD:
- Sulfatide alterations: AD brain shows reduced sulfatide levels
- Myelin vulnerability: White matter damage in AD includes sulfatide loss
- Cognitive function: Sulfatide deficiency correlates with cognitive decline
- Amyloid interaction: Sulfatides may modulate amyloid processing
While primarily a gray matter disorder, PD involves white matter changes:
- Oligodendrocyte dysfunction: GAL3ST1 may be affected in PD
- Myelin alterations: White matter abnormalities in PD
- Iron metabolism: Sulfatide and iron interactions relevant to PD pathogenesis
GAL3ST1 sits at the intersection of myelin-related pathways:
- PLP/DM20 metabolism: Sulfatides interact with proteolipid proteins
- MBP interactions: Myelin basic protein associations
- ** Cholesterol metabolism**: Myelin lipid homeostasis
- Oligodendrocyte development: Affects OPC differentiation
GAL3ST1 connects to broader lipid metabolism:
- Ceramide metabolism: Shares precursors with other ceramide species
- Sphingolipid pathways: Central node in sphingolipid biosynthesis
- Fatty acid metabolism: Palmitate and other fatty acids as precursors
- Cholesterol trafficking: Myelin cholesterol homeostasis
GAL3ST1 affects inflammatory responses:
- Cytokine regulation: Sulfatides modulate microglial activation
- Immune cell trafficking: Affects immune cell infiltration
- Autoimmunity: CD1d-sulfatide-NKT axis in demyelination
Modulating GAL3ST1 has therapeutic potential:
- Enzyme replacement: Recombinant protein can restore activity
- Gene therapy: AAV-mediated delivery to oligodendrocytes
- Substrate reduction: Reduce toxic galactocerebroside accumulation
- Combination approaches: Enhance remyelination alongside enzyme delivery
| Approach |
Status |
Notes |
| Enzyme replacement |
Preclinical |
Recombinant GAL3ST1 delivery |
| Gene therapy (AAV) |
Preclinical |
Target oligodendrocytes |
| Gene therapy (ex vivo) |
Clinical trials |
Hematopoietic stem cell gene therapy |
| Substrate reduction |
Preclinical |
Inhibition of galactocerebroside synthesis |
| HSCT |
Standard of care |
Early treatment for MLD |
The FDA-approved gene therapy Libmeldy (atidarsagene autotemcel) for MLD utilizes ex vivo gene correction of hematopoietic stem cells .
- BBB delivery: Enzyme/gene must reach CNS oligodendrocytes
- Timing: Early intervention before irreversible damage
- Immune response: Anti-enzyme antibodies may develop
- Systemic effects: Enzyme affects multiple tissues
GAL3ST1 connects to numerous NeuroWiki pages:
¶ Proteins and Genes